GEn1E Lifesciences enters option agreement to license University of Maryland's MUC-ED peptide Nov. 21, 2018
IMV amends phase Ib/II study to develop DPX-Survivac as monotherapy for recurrent ovarian cancer Nov. 21, 2018
Phase I study evaluates mogamulizumab with durvalumab or tremelimumab in advanced solid tumors Nov. 21, 2018
Splice variant in HSD17B13 protects against histological damage in NAFLD patients from South America Nov. 21, 2018
RSS